Prostate Cancer Drug Lupron Slows Memory Loss In Female Alzheimer’s Patients

Prostate Cancer Drug Lupron Slows Memory Loss In Female Alzheimer’s Patients
A recent study published in the Journal of Alzheimer's Disease titled "A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks" showed that women with Alzheimer's disease evidenced a stable cognition, for a period of one year, when they received a drug regimen that contained a drug commonly used to treat advanced prostate cancer, Lupron. The study was carried on by researchers from the University of Wisconsin-Madison (UW). Dr. Craig Atwood is a professor at the UW School of Medicine and Public Health and is also the co-leading author of this study. He noted that this is the first therapy that worked as a memory loss stabilizer over a one year period. The clinical trial followed 109 women suffering from mild to moderate forms of Alzheimer's disease; this trial was initiated by Dr. Richard Bowen at the Voyager Pharmaceutical Corporation. Some patients received a treatment that consisted of leuprolide acetate, frequently used to treat men with cancer and endometriosis in women, and an acetylcholineesterase inhibitor like 
Subscribe or to access all post and page content.